Copeland Capital Management LLC Decreases Stock Holdings in Zoetis Inc. $ZTS

Key Points

• Copeland Capital Management LLC cut its Zoetis stake by 98.0%, selling 76,007 shares and leaving it with 1,570 shares worth about $198,000 at quarter-end.
• Zoetis beat quarterly estimates (EPS $1.48 vs. $1.40; revenue $2.39B vs. $2.36B) and set FY2026 guidance of 7.00–7.10 EPS, roughly in line with analysts' ~7.02 EPS expectation.
• The company declared a quarterly dividend of $0.53 (annualized $2.12, ~1.8% yield; ex-dividend April 20), while analysts’ consensus rating remains a "Hold" with a $152.25 price target.

Copeland Capital Management LLC reduced its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 98.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,570 shares of the company's stock after selling 76,007 shares during the period. Copeland Capital Management LLC's holdings in Zoetis were worth $198,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC increased its position in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock worth $25,000 after purchasing an additional 144 shares in the last quarter. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis in the 4th quarter worth $25,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis in the 4th quarter worth $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis during the 3rd quarter worth $31,000. Finally, Holos Integrated Wealth LLC purchased a new position in Zoetis during the 4th quarter worth $32,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $116.92 on Friday. The business has a fifty day moving average of $120.83 and a 200 day moving average of $125.53. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market capitalization of $49.18 billion, a price-to-earnings ratio of 19.42, a price-to-earnings-growth ratio of 1.77 and a beta of 0.98.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the previous year, the business earned $1.40 EPS. The company's quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts expect that Zoetis Inc. will post 7.02 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis's dividend payout ratio is 35.22%.

Analysts Set New Price Targets

A number of research firms have commented on ZTS. Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a research note on Saturday, February 21st. Citigroup began coverage on Zoetis in a research note on Wednesday, April 15th. They set a "buy" rating and a $145.00 price target on the stock. UBS Group set a $136.00 price objective on shares of Zoetis in a report on Thursday, January 29th. BTIG Research reaffirmed a "buy" rating and issued a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $152.25.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.